Thermo Fisher Scientific Inc. (NYSE:TMO) has been assigned a consensus recommendation of “Buy” from the seventeen analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $224.38.
Several analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research report on Monday, April 30th. ValuEngine downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, June 20th. Finally, Morgan Stanley reduced their price objective on shares of Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating for the company in a research report on Wednesday, April 11th.
Get Thermo Fisher Scientific alerts:
Shares of Thermo Fisher Scientific stock opened at $205.57 on Tuesday. Thermo Fisher Scientific has a 52-week low of $170.07 and a 52-week high of $226.44. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $83.34 billion, a P/E ratio of 21.66, a PEG ratio of 1.52 and a beta of 1.10.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 25th. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The company had revenue of $5.85 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the previous year, the firm earned $2.08 earnings per share. The firm’s quarterly revenue was up 22.8% on a year-over-year basis. equities research analysts anticipate that Thermo Fisher Scientific will post 10.9 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 16th. Stockholders of record on Friday, June 15th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.17%.
In other news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 4th. The shares were sold at an average price of $212.00, for a total value of $530,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director C Martin Harris sold 206 shares of Thermo Fisher Scientific stock in a transaction on Friday, May 18th. The shares were sold at an average price of $214.43, for a total transaction of $44,172.58. Following the completion of the transaction, the director now directly owns 5,106 shares in the company, valued at $1,094,879.58. The disclosure for this sale can be found here. Insiders have sold a total of 97,706 shares of company stock valued at $21,125,673 in the last 90 days. Insiders own 0.49% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.0% in the 1st quarter. BlackRock Inc. now owns 24,582,453 shares of the medical research company’s stock valued at $5,075,294,000 after acquiring an additional 475,267 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Thermo Fisher Scientific by 0.3% in the 1st quarter. Wells Fargo & Company MN now owns 3,198,908 shares of the medical research company’s stock valued at $660,446,000 after acquiring an additional 9,820 shares during the period. Clearbridge Investments LLC increased its holdings in shares of Thermo Fisher Scientific by 5.3% in the 4th quarter. Clearbridge Investments LLC now owns 2,862,399 shares of the medical research company’s stock valued at $543,512,000 after acquiring an additional 143,518 shares during the period. Brown Advisory Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.4% in the 1st quarter. Brown Advisory Inc. now owns 2,144,864 shares of the medical research company’s stock valued at $442,830,000 after acquiring an additional 49,320 shares during the period. Finally, Royal Bank of Canada increased its holdings in shares of Thermo Fisher Scientific by 1.5% in the 1st quarter. Royal Bank of Canada now owns 2,011,731 shares of the medical research company’s stock valued at $415,343,000 after acquiring an additional 30,355 shares during the period. 85.76% of the stock is currently owned by institutional investors and hedge funds.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
